Psychedelic Therapy in California: Current Legal Status in 2026
Psychedelic-assisted therapy has gained national attention as research continues to demonstrate potential benefits for depression, PTSD, substance use disorders, and end-of-life anxiety. Many patients and providers are asking whether psychedelic therapy is legally available in California.
As of 2026, California does not have a statewide licensed psychedelic services program comparable to Oregon’s regulated psilocybin model. However, research infrastructure has expanded, and certain local decriminalization measures exist. Understanding the distinction between legalization, decriminalization, and research authorization is important.
Current California Legal Status in 2026
Classic psychedelics including psilocybin, psilocin, DMT, and mescaline remain classified as Schedule I controlled substances under both federal law and California law. General possession, sale, and distribution remain illegal outside of approved research settings.
Several legislative efforts have attempted to change this framework:
SB 58 (2023) proposed decriminalizing limited personal possession of certain psychedelics for adults. The bill was vetoed by Governor Gavin Newsom and did not become law.
SB 1012 (2024) proposed creating a regulated psychedelic-assisted therapy licensing system. The bill failed in committee and did not advance.
SB 751 (2025–2026) proposed a limited psilocybin pilot program for veterans and former first responders. The bill did not pass.
Officially, California has not enacted statewide legalization or a licensed service model for psychedelic therapy as of February 2026.
Research Expansion Under AB 1103
The most significant statewide development occurred in October 2025 when Governor Newsom signed AB 1103 into law. This legislation does not legalize public access to psychedelic therapy. Instead, it streamlines and modernizes California’s research approval process for Schedule I and II substances through updates to the Research Advisory Panel of California.
The practical impact of AB 1103 includes:
More efficient review and oversight of controlled substance research
Greater clarity for academic institutions conducting psychedelic studies
Expanded potential for clinical trials within the state
This law strengthens California’s position as a major research hub but does not create licensed psychedelic clinics or legal therapeutic access for the general public.
Legal Access Pathways in 2026
Currently, the primary lawful pathway for psychedelic-assisted therapy in California is participation in approved clinical trials.
Major research institutions in California continue to conduct studies involving psilocybin and other psychedelic compounds for:
Major depressive disorder
Treatment-resistant depression
Posttraumatic stress disorder
Substance use disorders
Existential distress in serious illness
These trials operate under FDA Investigational New Drug protocols and institutional review board oversight.
Outside of approved research settings, psychedelic-assisted therapy remains legally prohibited at the state and federal level.
Local Decriminalization Measures
Several California cities have passed resolutions making enforcement of laws related to entheogenic plants and fungi among the lowest law enforcement priorities. Cities such as Oakland, Santa Cruz, Arcata, Berkeley, and San Francisco have adopted such measures.
It is critical to understand that:
These resolutions do not change state law.
They do not legalize commercial sales.
They do not prevent state or federal enforcement.
They typically deprioritize enforcement rather than remove criminal statutes.
Local decriminalization reduces enforcement risk in certain municipalities but does not equate to legal therapeutic practice.
Patient Considerations
Patients seeking psychedelic-assisted therapy in California should consider:
Enrollment in approved clinical trials
Reviewing eligibility criteria carefully
Verifying research site credentials
Understanding informed consent processes
Outlook for 2026 and Beyond
California’s legislative pattern indicates cautious progression. While broad legalization efforts have stalled, research facilitation has advanced. This suggests that the state is prioritizing data collection and clinical evidence before expanding public access. Future legislative proposals may reemerge, particularly focused on veterans or targeted pilot programs. However, as of 2026, no regulated public psychedelic therapy system exists in California.
Final Thoughts
At Heron & Lily Psychiatric Services, we closely monitor developments in psychedelic-assisted therapy. At this time, psychedelic treatment in California remains limited to approved research settings and is not available as a standard outpatient service. For individuals interested in this area of care, participation in a regulated clinical trial remains the most legally sound and compliant pathway.
As the scientific evidence base grows and federal scheduling policies continue to evolve, California’s regulatory landscape may change. Until then, it is important to distinguish clearly between formal research participation, local decriminalization measures, and full legal therapeutic access. Our team is committed to providing guidance grounded in current law, clinical responsibility, and patient safety.
References
California Legislative Information. (2023). SB 58 controlled substances: decriminalization of certain plant and fungal substances. https://leginfo.legislature.ca.gov
California Legislative Information. (2024). SB 1012 psychedelic-assisted therapy regulation proposal. https://leginfo.legislature.ca.gov
California Legislative Information. (2025). SB 751 psilocybin pilot program for veterans. https://leginfo.legislature.ca.gov
California Legislative Information. (2025). AB 1103 controlled substances research modernization. https://leginfo.legislature.ca.gov
U.S. Drug Enforcement Administration. (2024). Drug scheduling and controlled substances. https://www.dea.gov
